MX2019010341A - Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos. - Google Patents

Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos.

Info

Publication number
MX2019010341A
MX2019010341A MX2019010341A MX2019010341A MX2019010341A MX 2019010341 A MX2019010341 A MX 2019010341A MX 2019010341 A MX2019010341 A MX 2019010341A MX 2019010341 A MX2019010341 A MX 2019010341A MX 2019010341 A MX2019010341 A MX 2019010341A
Authority
MX
Mexico
Prior art keywords
red blood
blood cell
cell levels
erythropoietin receptor
receptor activators
Prior art date
Application number
MX2019010341A
Other languages
English (en)
Inventor
Kumar Ravindra
Scott Pearsall Robert
SHEEHRA Jasbir
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/004659 external-priority patent/WO2010019261A1/en
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MX2019010341A publication Critical patent/MX2019010341A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen composiciones para incrementar los niveles de glóbulos rojos o tratamiento de anemia que comprende activadores del receptor de eritropoyetina y un polipéptido de Activina RIIB (ActRllB) variante teniendo un residuo de leucina reemplazado por un residuo de aminoácido ácido en donde el polipéptido ActRllB variante tiene una afinidad reducida para activina B y pueden ser denominados como una Trampa GDF. También se describen métodos para el uso de estas composiciones.
MX2019010341A 2009-08-13 2012-02-13 Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos. MX2019010341A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2009/004659 WO2010019261A1 (en) 2008-08-14 2009-08-13 Use of gdf traps to increase red blood cell levels
US12/583,177 US8058229B2 (en) 2008-08-14 2009-08-13 Method of increasing red blood cell levels or treating anemia in a patient
US30590110P 2010-02-18 2010-02-18

Publications (1)

Publication Number Publication Date
MX2019010341A true MX2019010341A (es) 2019-10-21

Family

ID=43586530

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012001916A MX2012001916A (es) 2009-08-13 2010-08-13 Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos.
MX2019010341A MX2019010341A (es) 2009-08-13 2012-02-13 Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012001916A MX2012001916A (es) 2009-08-13 2010-08-13 Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos.

Country Status (14)

Country Link
EP (3) EP3117829B1 (es)
JP (4) JP5909446B2 (es)
KR (5) KR101882521B1 (es)
CN (7) CN113082194A (es)
AU (1) AU2010282361B2 (es)
BR (2) BR112012003232B1 (es)
CA (1) CA2770822C (es)
ES (2) ES2844123T3 (es)
HK (2) HK1223818A1 (es)
IL (6) IL287990B (es)
MX (2) MX2012001916A (es)
NZ (3) NZ623113A (es)
RU (2) RU2592670C2 (es)
WO (1) WO2011020045A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332977B1 (en) 2004-07-23 2015-11-25 Acceleron Pharma Inc. ActRII receptor polypeptides
KR20180030264A (ko) 2005-11-23 2018-03-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN104548056B (zh) 2007-02-09 2022-09-09 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
EP2207562B1 (en) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
TWI748373B (zh) 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
EP3845239A1 (en) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
CN102656187A (zh) 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
BR112014009528B1 (pt) * 2011-10-17 2020-12-29 Acceleron Pharma, Inc. usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
AU2013334659B2 (en) * 2012-10-24 2019-07-11 Celgene Corporation Biomarker for use in treating anemia
AU2013334660B2 (en) * 2012-10-24 2018-08-09 Celgene Corporation Methods for treating anemia
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
EP3119418B1 (en) 2014-03-21 2022-02-23 Acceleron Pharma Inc. Composition for use in a method of treating or preventing anemia by inhibiting activin b and gdf11
US9850298B2 (en) * 2014-06-13 2017-12-26 Acceleron Pharma Inc. Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
WO2016069925A1 (en) 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
PT3227675T (pt) * 2014-12-03 2023-05-30 Celgene Corp Antagonistas da ativina-actrii e utilizações para tratamento da síndrome mielodisplásica
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016128523A1 (en) * 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
EP3286206B1 (en) 2015-04-22 2021-02-17 Biogen MA Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
JP2018522579A (ja) * 2015-05-20 2018-08-16 セルジーン コーポレイション アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
US20170240639A1 (en) * 2016-02-22 2017-08-24 Acceleron Pharma Inc. Actrii antagonists for use in increasing immune activity
PL3496739T3 (pl) 2016-07-15 2021-10-11 Acceleron Pharma Inc. Kompozycje zawierające polipeptydy actriia do stosowania w leczeniu nadciśnienia płucnego
WO2018022762A1 (en) * 2016-07-27 2018-02-01 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis
CA3039074A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Compositions and method for treating kidney disease
EP3523328A4 (en) * 2016-10-05 2020-04-01 Acceleron Pharma Inc. ACTRIIB VARIANT PROTEINS AND USES THEREOF
CA3043184A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
US20200101134A1 (en) 2017-06-14 2020-04-02 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
AU2019206634B2 (en) 2018-01-12 2024-06-27 Keros Therapeutics, Inc. Activin receptor type IIB variants and methods of use thereof
JP7405772B2 (ja) * 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
EP3873441A4 (en) * 2018-12-10 2022-06-29 Arshintseva, Elena Valentinovna A new use of the poloxamer as a pharmacologically active substance
CN111466337B (zh) * 2020-05-19 2022-04-19 山东大学齐鲁医院 一种腹主动脉瘤动物模型及其构建方法
CN115317589A (zh) * 2022-09-05 2022-11-11 中国海洋大学 脯氨酰羟化酶抑制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
CN100567322C (zh) 1999-01-21 2009-12-09 梅塔莫菲克斯公司 抑制生长分化因子活性的多肽及表达该多肽的细胞
AU784091B2 (en) * 2000-05-15 2006-02-02 F. Hoffmann-La Roche Ag New pharmaceutical composition
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
EP1463823B1 (en) * 2001-12-06 2013-03-06 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (epo)
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
JP5390070B2 (ja) * 2003-02-07 2014-01-15 プロメティック、バイオサイエンシーズ、インコーポレーテッド 赤血球形成刺激薬としての中鎖脂肪酸、グリセリド、および類似体
GB0304424D0 (en) * 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
EP2332977B1 (en) 2004-07-23 2015-11-25 Acceleron Pharma Inc. ActRII receptor polypeptides
BRPI0518728A2 (pt) * 2004-12-09 2008-12-02 Univ Pittsburgh vacinas para a resposta rÁpida À pandemia de gripe aviÁria
KR20080003929A (ko) * 2005-04-26 2008-01-08 아지노모토 가부시키가이샤 골수 적혈구 전구 세포 분화 촉진제
JP5361386B2 (ja) * 2005-10-07 2013-12-04 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ マトリックスメタロプロテイナーゼ１１ワクチン
US8067562B2 (en) * 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100003190A1 (en) * 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
KR102223231B1 (ko) 2006-12-18 2021-03-08 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉ 길항물질과 적혈구 수준을 증가시키기 위한 이의 용도
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
WO2009158015A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI748373B (zh) * 2008-08-14 2021-12-01 美商艾瑟勒朗法瑪公司 使用gdf阱以增加紅血球水平

Also Published As

Publication number Publication date
IL275851A (en) 2020-08-31
IL252045A0 (en) 2017-06-29
CN105535938A (zh) 2016-05-04
RU2642302C1 (ru) 2018-01-24
EP3117829A1 (en) 2017-01-18
EP2464369A1 (en) 2012-06-20
NZ712943A (en) 2017-08-25
CN105561295B (zh) 2020-03-20
CN102655872A (zh) 2012-09-05
KR20200124322A (ko) 2020-11-02
BR112012003232A2 (pt) 2016-11-22
NZ623113A (en) 2015-10-30
AU2010282361B2 (en) 2015-03-19
CN102655872B (zh) 2016-01-20
CN105561295A (zh) 2016-05-11
BR112012003232B1 (pt) 2022-02-22
KR20180085825A (ko) 2018-07-27
WO2011020045A9 (en) 2011-06-03
RU2017145301A (ru) 2019-06-24
HK1223818A1 (zh) 2017-08-11
IL252046B (en) 2020-07-30
IL218052A (en) 2017-05-29
KR20120054024A (ko) 2012-05-29
JP2018177816A (ja) 2018-11-15
ES2844123T3 (es) 2021-07-21
CA2770822A1 (en) 2011-02-17
AU2010282361A1 (en) 2012-03-15
EP2464369B1 (en) 2020-03-11
RU2732229C2 (ru) 2020-09-14
IL252044A0 (en) 2017-06-29
RU2592670C2 (ru) 2016-07-27
NZ598348A (en) 2014-05-30
KR101882521B1 (ko) 2018-07-27
JP5909446B2 (ja) 2016-04-26
CN105535938B (zh) 2022-04-26
IL252045B (en) 2020-05-31
KR102606494B1 (ko) 2023-11-24
CN113577291A (zh) 2021-11-02
JP6860533B2 (ja) 2021-04-14
MX2012001916A (es) 2012-05-22
KR102170682B1 (ko) 2020-10-28
ES2796121T3 (es) 2020-11-25
HK1224199A1 (zh) 2017-08-18
CN105412908A (zh) 2016-03-23
BR122020019169B1 (pt) 2022-09-27
JP2013501816A (ja) 2013-01-17
IL218052A0 (en) 2012-04-30
IL252046A0 (en) 2017-06-29
IL275851B (en) 2021-12-01
EP3838919A1 (en) 2021-06-23
IL287990B (en) 2022-07-01
WO2011020045A1 (en) 2011-02-17
IL287990A (en) 2022-01-01
JP2020203953A (ja) 2020-12-24
CN113171442A (zh) 2021-07-27
RU2017145301A3 (es) 2019-06-24
CA2770822C (en) 2020-03-24
KR20230003452A (ko) 2023-01-05
CN113082194A (zh) 2021-07-09
RU2020127574A (ru) 2022-02-21
CN105412908B (zh) 2021-08-24
IL252044B (en) 2019-11-28
KR20190111158A (ko) 2019-10-01
JP2016034981A (ja) 2016-03-17
RU2012109393A (ru) 2013-09-20
EP3117829B1 (en) 2020-10-07
EP2464369A4 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
MX2019010341A (es) Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos.
EA201590887A1 (ru) Композиция
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201201036A1 (ru) Целевые геномные изменения
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
IN2014DN09346A (es)
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX2013001580A (es) Composiciones que comprenden un polipeptido que tiene actividad de incremento celulolitico y un licor, y usos de las mismas.
BR112014015905A8 (pt) composição
WO2011141110A3 (de) Photostabilisatoren
BR112014015908A2 (pt) composição
TR201905272T4 (tr) İmmünojenik bileşim.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
EA201201623A1 (ru) Лечение диабета 2 типа
WO2010120541A3 (en) Compositions and methods for modulating the activity of complement regulatory proteins on target cells
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2013022550A3 (en) Small molecule inhibitors of ebola and lassa fever viruses
PH12014502551B1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
PH12014501781A1 (en) Solid forms comprising inhibitors of hcv ns5a, compositions thereof, and uses therewith
BRPI0914940A8 (pt) Composições nutritivas contendo punicalaginas
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
EA201190274A1 (ru) Конструкции casb7439